Belgium-based AgomAb Therapeutics has raised funds in a series A round to support the development of molecular therapies for the regeneration of damaged tissues.

The €21m financing round was co-led by V-Bio Ventures and Advent France Biotechnology, with participation from Boehringer Ingelheim Venture Fund, Omnes and Pontifax.

AgomAb is developing agonistic monoclonal antibody molecules that induce molecular and cellular repair mechanisms with potential for restoring organ function in fibrotic, inflammatory, autoimmune and degenerative conditions.

Founded in 2017, the company builds on the work by the University of Torino, Italy professor Paolo Michieli, whose research led to immunoglobulins with anti-fibrotic and pro-regenerative activity comparable to hepatocyte growth factor (HGF).

HGF is a pleiotropic protein that is known to possess therapeutic potential.

“The regenerative and anti-fibrotic potential of HGF has been known for decades, but its translation to the clinic has been challenging.”

In alliance with Dutch drugmaker argenx, AgomAb generated a set of preclinical programmes with various applications across multiple therapeutic areas.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Paolo Michieli said: “The regenerative and anti-fibrotic potential of HGF has been known for decades, but its translation to the clinic has been challenging.

“While HGF-mimetic agomAbs maintain the full therapeutic potential of HGF, they display the excellent drug-like properties of antibodies, holding the promise for regeneration of fibrotic tissues in a variety of clinical indications.”

AgomAb also exercised an exclusive licence agreement with argenx for leveraging HGF-mimetic SIMPLE Antibodies developed under the latter’s Innovative Access Program.

AgomAb board of directors chairman John Haurum said: “Anti-fibrotic regenerative stimulation of the HGF pathway is an exciting novel approach which holds promise in a range of hard-to-treat inflammatory conditions.”